List view / Grid view
Through a new acquisition, Boehringer Ingelheim will have rights to…
Through a new acquisition, Boehringer Ingelheim will have rights to a platform that enables the design of immuno-oncology combination therapies in one single agent.
According to a new report, biologics are forecast to have…
According to a new report, biologics are forecast to have $120 billion greater sales than small molecules by 2027.
A report has suggested that number of Orphan Drug Designations…
A report has suggested that number of Orphan Drug Designations in both the US and Europe is declining, possibly due to prices and political changes.
